Ramón Salazar logo Catalan Institute of Oncology (ICO) logo

Ramón Salazar

General Director, Catalan Institute of Oncology (ICO)(Spain)


Ramon Salazar is currently the General Director at the Catalan Institute of Oncology and senior lecturer at the University of Barcelona.

Dr. Salazar completed his MD and PhD at the Hospital Santa Creu i Sant Pau in Barcelona. He then undertook a research fellowship at the Beatson Oncology Centre (Cancer Research Campaign) in Glasgow, Scotland, with funding from a European Society of Medical Oncology (ESMO) clinical fellowship grant, and underwent further training at the Neuroendocrine Oncology Unit of the University of Uppsala in Uppsala, Sweden, under the direction of Kjell Öberg.

Dr. Salazar has been a faculty member of the European Society of Oncological Medicine (ESMO) and of the Spanish Society of Medical Oncology (SEOM) for more than 15 years. He also holds the position of vice-chair of the executive committee of the Spanish Cooperative Group for the Treatment of Gastrointestinal Tumor (Group TTD), member of national and international research networks in national (CIBERONC, Euracan, Eucancan, Colossus, ACRCelerate, etc) and founding chair of the Spanish Group Neuroendocrine Tumor (GETNE) and member of scientific advisory board of international projects. He has been part of the executive committee of the ENETS (European Society of Neuroendocrine Tumors), where he has coordinated the updating of the European Guidelines for Neuroendocrine Digestive Tumors, and is leading a European Phase Ill clinical Seqtor trial.

He has published more than 200 peer-reviewed articles in medical journals, and written numerous book chapters and monographs, as well as online content. He has also organized a number of symposia and teaching activities at institutes including the University of Barcelona and the European School of Oncology.


Why WIN

One of the most exciting initiatives in personalized cancer medicine is the WIN Consortium.  Only through international networking we will able to achieve breakthrough advances in cancer research.

Ramón Salazar logo

Ramón Salazar

General Director, Catalan Institute of Oncology (ICO)(Spain)


Catalan Institute of Oncology (ICO) logo

Ramon Salazar is currently the General Director at the Catalan Institute of Oncology and senior lecturer at the University of Barcelona.

Dr. Salazar completed his MD and PhD at the Hospital Santa Creu i Sant Pau in Barcelona. He then undertook a research fellowship at the Beatson Oncology Centre (Cancer Research Campaign) in Glasgow, Scotland, with funding from a European Society of Medical Oncology (ESMO) clinical fellowship grant, and underwent further training at the Neuroendocrine Oncology Unit of the University of Uppsala in Uppsala, Sweden, under the direction of Kjell Öberg.

Dr. Salazar has been a faculty member of the European Society of Oncological Medicine (ESMO) and of the Spanish Society of Medical Oncology (SEOM) for more than 15 years. He also holds the position of vice-chair of the executive committee of the Spanish Cooperative Group for the Treatment of Gastrointestinal Tumor (Group TTD), member of national and international research networks in national (CIBERONC, Euracan, Eucancan, Colossus, ACRCelerate, etc) and founding chair of the Spanish Group Neuroendocrine Tumor (GETNE) and member of scientific advisory board of international projects. He has been part of the executive committee of the ENETS (European Society of Neuroendocrine Tumors), where he has coordinated the updating of the European Guidelines for Neuroendocrine Digestive Tumors, and is leading a European Phase Ill clinical Seqtor trial.

He has published more than 200 peer-reviewed articles in medical journals, and written numerous book chapters and monographs, as well as online content. He has also organized a number of symposia and teaching activities at institutes including the University of Barcelona and the European School of Oncology.


Why WIN

One of the most exciting initiatives in personalized cancer medicine is the WIN Consortium.  Only through international networking we will able to achieve breakthrough advances in cancer research.